CG Oncology (NASDAQ: CGON) investors back directors, EY and pay plan
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
CG Oncology, Inc. reported the results of its 2026 annual stockholder meeting. As of the April 7, 2026 record date, 88,009,980 shares of common stock were outstanding and entitled to vote. Stockholders elected Class II directors Christina Rossi and Victor Tong, Jr. to terms running until the 2029 annual meeting.
Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In advisory votes, stockholders approved the compensation of named executive officers and expressed a preference for holding future advisory votes on executive pay every year, and the company will follow an annual frequency.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 88,009,980 shares
Rossi votes for: 67,531,501 shares
Tong votes for: 62,401,874 shares
+3 more
6 metrics
Shares entitled to vote
88,009,980 shares
Common stock outstanding as of April 7, 2026 record date
Rossi votes for
67,531,501 shares
Shares voted for election of director Christina Rossi
Tong votes for
62,401,874 shares
Shares voted for election of director Victor Tong, Jr.
Auditor ratification for
83,711,522 shares
Shares voted for ratifying Ernst & Young LLP as auditor
Say-on-pay for
65,894,959 shares
Shares voted for advisory approval of executive compensation
Annual frequency support
66,962,791 shares
Shares selecting 1-year frequency for advisory pay votes
Key Terms
broker non-votes, independent registered public accounting firm, advisory vote, emerging growth company, +1 more
5 terms
broker non-votes financial
"Shares Voted For ... Shares Voted Withhold ... Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the selection ... as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
advisory vote financial
"advisory vote on executive compensation"
An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
record date financial
"As of April 7, 2026, the record date for the Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
FAQ
What did CG Oncology (CGON) stockholders vote on at the 2026 annual meeting?
Stockholders voted on electing two Class II directors, ratifying Ernst & Young LLP as auditor, approving executive compensation on an advisory basis, and choosing how often to hold future advisory pay votes. These items shape board composition, oversight, and say-on-pay practices.
Who was elected to CG Oncology’s board at the 2026 annual meeting?
Stockholders elected Christina Rossi and Victor Tong, Jr. as Class II directors to serve until the 2029 annual meeting. Their elections were based on the proxy statement disclosures and will help guide the company’s governance and strategic oversight over the coming years.
Did CG Oncology (CGON) stockholders approve executive compensation in 2026?
Yes, stockholders approved, on an advisory basis, the compensation of CG Oncology’s named executive officers. The vote reflects stockholder views on the company’s pay practices as described in the proxy statement, though it is non-binding and does not directly change existing compensation arrangements.
How often will CG Oncology hold say-on-pay votes after the 2026 meeting?
Stockholders indicated a preference for annual advisory votes on named executive officer compensation. In response, CG Oncology determined that future say-on-pay votes will be held every year until the next required advisory vote on the frequency of such stockholder approvals.
Which audit firm did CG Oncology stockholders ratify for the 2026 fiscal year?
Stockholders ratified the selection of Ernst & Young LLP as CG Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026. This ratification supports the audit committee’s choice of external auditor for the company’s financial reporting.